StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck Zetia (ezetimibe, legacy pre-Organon spin-off) by Year

Zetia (ezetimibe, legacy pre-Organon spin-off) — International reported growth YoY (%) (%)

Merck Zetia (ezetimibe, legacy pre-Organon spin-off): -29.0% in FY2019, down 11.0 pts from a year earlier. No newer figure appears in the documents we track.

Latest, FY2019
-29.0%
Period ended Dec 31, 2019
Change on a year earlier
-11.0 pts
-18.0% in FY2018
History
3 years
Since FY2017
Sources
3
Documents cited below

Where the FY2019 figure comes from

“|| Zetia | 590 | 857 | -31 | 14 | 45 | -69 | 575 | 813 | -29”

Source: Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗

Reported in Form 8-K Table 3a / 3b Product Sales.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedZetia (ezetimibe, legacy pre-Organon spin-off) — International reported growth YoY (%) (%)Year on yearSource
FY2019Dec 31, 2019-29.0%-11.0 ptsForm 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
FY2018Dec 31, 2018-18.0%-20.0 ptsForm 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
FY2017Dec 31, 20172.0%–Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗

Cite this data

StockData. (2026). Merck Zetia (ezetimibe, legacy pre-Organon spin-off) (%), annual FY2017–FY2019 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-zetia-intl-nom-yoy

See every metric in the Merck KPI table. Data updated Oct 26, 2026.